Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein Note=Ligand binding leads to internalization and translocation to an antigen-processing compartment. |
Domain |
PF00047 Immunoglobulin domain PF13895 Immunoglobulin domain |
Function |
Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Involved in the down-regulation of the immune response and the development of tolerance, e.g. towards transplants. Interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. |
Biological Process |
GO:0002250 adaptive immune response GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0002683 negative regulation of immune system process GO:0002761 regulation of myeloid leukocyte differentiation GO:0002762 negative regulation of myeloid leukocyte differentiation GO:0030099 myeloid cell differentiation GO:0030316 osteoclast differentiation GO:0045637 regulation of myeloid cell differentiation GO:0045638 negative regulation of myeloid cell differentiation GO:0045670 regulation of osteoclast differentiation GO:0045671 negative regulation of osteoclast differentiation GO:0061614 pri-miRNA transcription from RNA polymerase II promoter GO:1902105 regulation of leukocyte differentiation GO:1902106 negative regulation of leukocyte differentiation GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902894 negative regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1903706 regulation of hemopoiesis GO:1903707 negative regulation of hemopoiesis |
Molecular Function |
GO:0003823 antigen binding |
Cellular Component | - |
KEGG |
hsa04380 Osteoclast differentiation |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between LILRB4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between LILRB4 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of LILRB4 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of LILRB4 in various data sets.
|
Points in the above scatter plot represent the mutation difference of LILRB4 in various data sets.
|
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LILRB4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LILRB4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LILRB4. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LILRB4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of LILRB4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between LILRB4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | LILRB4 |
Name | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 |
Aliases | LIR-5; ILT3; HM18; LIR5; CD85k; ILT-3; CD85 antigen-like family member K; immunoglobulin-like transcript 3; ...... |
Chromosomal Location | 19q13.4 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting LILRB4 collected from DrugBank database. |
There is no record. |